# Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

> **NCT04377555** · PHASE4 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 179 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing

## Interventions

- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT04377555
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-30
- **Primary completion:** 2022-12-15
- **Final completion:** 2025-11-11
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04377555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04377555, "Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04377555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*